Nalu Reports 94% Response Rate in Largest Real-World Study of Peripheral Nerve Stimulation Device
核心洞察
Nalu Medical (搜索) published real-world data from 2,273 patients with chronic pain (搜索) treated using their micro-IPG peripheral nerve (搜索) stimulation system, representing the largest dataset for a permanent PNS device.
The study demonstrated a 94% responder rate as measured by Patient Global Impression of Change, confirming results from the previous COMFORT randomized controlled trial.
Combined with published data showing 50% reduction in total healthcare costs, these findings support expanded insurance coverage for PNS therapy in chronic pain (搜索) management.
Nalu Medical (搜索) has published the largest real-world dataset on a permanent peripheral nerve (搜索) stimulation (PNS) device, demonstrating exceptional effectiveness in treating chronic pain (搜索) across 2,273 patients. The study, published in the Chronic Pain and Management Journal, establishes Nalu PNS as a medically necessary treatment for chronic pain conditions.
Unprecedented Real-World Evidence
The analysis of patients implanted with the Nalu micro-IPG PNS System (搜索) achieved a remarkable 94% responder rate as measured by the Patient Global Impression of Change (PGIC), a highly respected clinical assessment tool. This large sample size provides solid evidence of reliable effectiveness and supports the generalization of findings to the broader chronic pain (搜索) population.
"The consistent improvements observed across a large, diverse sample of real-world clinic patients treated in multiple anatomic regions and nerve combinations emphasizes the broad applicability of PNS therapy delivered by the Nalu micro-IPG PNS system (搜索)," said John Hatheway, MD, lead author of the paper.
Confirmation of Clinical Trial Results
These real-world data results confirm the outstanding 1-year published findings of the COMFORT Randomized Controlled Trial (RCT). The magnitude of the sample size supports generalizing those controlled trial findings to the population at large, providing robust evidence for the therapy's effectiveness in routine clinical practice.
Healthcare Economic Impact
The study's findings are strengthened by previously published data reporting a 50% reduction in total healthcare costs among patients receiving Nalu PNS therapy. Combined with the clinical effectiveness data, these findings provide strong real-world evidence that supports expanded coverage of PNS by private insurers.
Technology and Clinical Applications
The Nalu Neurostimulation System (搜索) delivers gentle electrical pulses to the nervous system to modulate pain signals before they reach the brain. The system consists of a battery-free, miniaturized implantable pulse generator (IPG) that is powered wirelessly by an externally worn Therapy Disc and controlled through a smartphone-based remote control app.
Despite its small size, the Nalu micro-IPG delivers treatment capabilities similar to larger IPGs while offering unique advantages including advanced waveforms, extensive programming options, exceptional upgradability, and an expected service life of 18 years.
Clinical Significance
Tom West, President and CEO of Nalu, emphasized the clinical impact: "These real-world results provide unmistakable evidence that the Nalu micro-IPG PNS System (搜索) is dramatically reshaping pain management. No permanent PNS system has undergone greater scrutiny or shown comparable performance. We are thrilled to see that our groundbreaking technology is able to provide reliable long-term pain relief to such a broad spectrum of patients."
The Nalu System is FDA-cleared for both Spinal Cord Stimulation (SCS) and Peripheral Nerve (搜索) Stimulation (PNS) indications, addressing chronic intractable pain (搜索) of the trunk, limbs, and peripheral nerve origins in adults.